Fig 1: Mettl14 modulated SCI by mediating EEF1A2 expression.A expressions of Mettl14, EEF1A2 proteins in spinal cord tissues detected by Western blot; (B) total m6A level detected by Dot blot assay; (C) locomotor ability detected by BBB locomotor rating scale; (D) neuronal function detected by inclined plane test; (E) pathological conditions of spinal cord assessed by HE staining; (F) apoptosis of spinal cord tissues detected by TUNEL staining; (G) expressions of TNF-α, IL-1β and IL-6 detected by ELISA. Data were expressed as mean ± SD and analyzed using independent t test, N = 5. * vs SCI + sh-NC group, p < 0.05; # vs SCI + sh-Mettl14 + sh-EEF1A2 group, p < 0.05.
Fig 2: METTL14 regulated α-klotho m6A modification. A α-Klotho m6A level in high glucose induced cells was examined by RIP-qPCR. **P < 0.01 vs. Control. B α-Klotho m6A level after overexpression or inhibition of METTL14 was examined by RIP-qPCR. **P < 0.01 vs. Vector. Data are presented as the mean ± SD (n = 3)
Fig 3: piRNA-14633 promotes CC progression by way of m6A RNA methylation. piRNA-14633 is overexpressed in cervical cancer. piRNA-14633 interactes with 3’UTR of METTL14 to increase METTL14 mRNA stability and promoted the methylase activity of METTL14 promoting the m6 A methylation levels of the downstream target (CYP1B1) and subsequently enhanced expression of CYP1B1, thereby contributed to tumorigenesis of CC
Fig 4: METTL14 was highly expressed in DN patients and high glucose-induced HRGECs. A–C Expression of METTL14 in kidney tissues of normal people and diabetic nephropathy patients was examined by qRT-PCR and western blot. Data are presented as the mean ± SD (n = 20); *P < 0.05, **P < 0.01 vs. normal. D–F Expression of METTL14 in glomerular endothelial cells was examined by qRT-PCR and western blot. G The m6A content was examined by colorimetric method. NG normal glucose, HM high mannitol, HG high glucose. Data are presented as the mean ± SD (n = 3); **P < 0.01 vs. NG
Fig 5: Overexpression METTL14 promote AML development. (a) CCK-8 was used to detect the proliferation of HL-60 cells affected by METTL14. (b) Flow cytometry was used to detect the apoptosis of HL-60 cells affected by METTL14. (c, d) Transwell assay was used to detect the migration and invasion of HL-60 cells affected by METTL14, bar = 100 µm. (e, f) Tumor volume and weight was detected in the tumor-bearing mice at 0, 7, 14, 21, and 28 days after tumor-bearing with HL-60 cells. (g) Proliferation was detected in vivo by Ki-67 staining assay affected by METTL14, bar = 25 µm. Data are presented as mean ± SD. *P < 0.05, ***P < 0.005, and ****P < 0.001.
Supplier Page from Abcam for Anti-METTL14 antibody